Interferon responses and spontaneous HCV clearance: Is it all a matter of fat?

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 3-5

  Feld, Jordan J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Apolipoprotein E (apo E); IL28B; Interferon responses; Lipoviral particles (LVP); Spontaneous clearance

Indexed keywords

APOLIPOPROTEIN E; CORE PROTEIN; INTERFERON; INTERLEUKIN 28; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN; VIRUS RNA;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE COURSE; EDITORIAL; GENOTYPE; HEPATITIS C VIRUS; INNATE IMMUNITY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL CLEARANCE; VIRION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; APOLIPOPROTEINS E; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; VIRION;

EID: 84862684162     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.04.003     Document Type: Editorial

References (23)

1. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 2010;102:63-74.
2. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-1097.
3. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale Jr M, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007;104:5848-5853.
4. Coller KE, Heaton NS, Berger KL, Cooper JD, Saunders JL, Randall G. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog 2012;8:e1002466.
5. Owen DM, Huang H, Ye J, Gale Jr M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009;394:99-108.
6. Mahley RW, Rall Jr SC, Apolipoprotein E. Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
7. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012;142:978-988.
8. Rehermann B, Hepatitis C. Virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Investig 2009;119:1745-1754.
9. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444.
10. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007;46:1548-1563.
11. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034-7039.
12. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
15. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.
16. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-1031, e1010.
17. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499-509.
18. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012;142:122-131.
19. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011;55:1195-1200.
20. Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012;57:32-38.
21. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011;53:14-22.
22. Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, et al. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 2010;139:1774-1783, e1771-6.
23. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-6928.